NovaBridge Biosciences
Business
NovaBridge Biosciences is a biotechnology company developing novel immunotherapy and ophthalmology drugs through internal programs and subsidiary entities. The pipeline includes givastomig, a CLDN18.2/4-1BB bispecific antibody for gastric cancers in Phase 2; VIS-101, a VEGF-A/ANG-2 bispecific antibody for wet AMD in Phase 2; uliledlimab, a CD73 antibody in Phase 2; and ragistomig, a PD-L1/4-1BB bispecific antibody in Phase 1. The company operates through subsidiary-based model with licensing and collaboration arrangements.
Summary from 20-F filed 2026-04-07
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-46.27M |
| Total assets | $260.52M |
| Total liabilities | $29.58M |
| Stockholders' equity | $230.94M |
| Operating cash flow | $-20.60M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NovaBridge Biosciences's CIK number?
NovaBridge Biosciences's SEC CIK number is 0001778016 (1778016). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NovaBridge Biosciences's SEC filings?
All of NovaBridge Biosciences's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.